Tirzepatide represents a revolutionary advancement in weight loss and metabolic health treatments. As the first dual GIP/GLP-1 receptor agonist, tirzepatide (branded as Zepbound for weight management and Mounjaro for type 2 diabetes) delivers superior results compared to single GLP-1 agonists, promoting significant appetite suppression, enhanced insulin sensitivity, delayed gastric emptying, and improved fat metabolism. Clinical […]